Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Launch new drugs...

    Launch new drugs without prior price approval: NPPA issues guidelines

    Written by Ruby Khatun Khatun Published On 2017-12-02T12:25:59+05:30  |  Updated On 18 Aug 2021 2:31 PM IST

    Through a recent notification the National Pharmaceutical Pricing Authority (NPPA), Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India has issued guidelines for examination of cases of the launch of new Drugs by pharma companies without obtaining prior price approval as required under the DPCO 2013.


    The NPPA had earlier begun the process of identification of new formulation launched by pharma companies on the basis of market data (Pharmatrac) without following the provisions contained in the Drugs Prices Control Order, 2013 (DPCO).


    The notice states that during the course of examination of replies submitted by various companies, it has been observed that the pharma companies have not submitted the requisite document(s) to support their contention.


    In order to bring clarity in the examination of cases of launch of new drugs "without prior price approvals" (WPA cases) and standardisation of documents to be submitted by the companies, it has been decided to follow a standard and uniform procedure, as mentioned in the paragraphs given hereunder, in respect of cases of launch of new drugs without prior price approval (WPA):


    WPA cases will be dropped in the following cases and the Company will be duly




    • The Company produces evidence (licence issued by State Drugs Controller (SDC)/ Drugs Controller General (India) (DCG(I)) and invoices and samples prior to 15th May 2013, certified by Chartered Accountant (CA) / Cost Accountant (CMA) in support of the claim that the formulation was launched before the DPCO 2013 came into effect;

    • If AIOCD-Pharmatrac data confirm that the formulation was launched prior to 15th May 2013.

    • If the company claims and produces sufficient evidence to support the claim that the formulation does not come under the definition of a "new drug" under paragraphs 2 (u) of the DPCO32013, i.e.,

      • (i) either the Company is not an "existing manufacturer" of the scheduled formulation; or

      • (ii) none of the components of the formulation is under Schedule I of the DPCO32013 as amended from time to time.



    • The Company claims are duly supported by sufficient evidence i.e. samples and invoices that the formulation. is a scheduled formulation and the ceiling price is complied therewith and followed in accordance with provisions of the DPCO, 2013.

    • The Company's claim that the formulation was never manufactured/ marketed by it is confirmed by AIOCD-Pharmatrac.

    • The Company has changed only the pack size and launched the new pack size(i) at a price equal to or less than the pro rata price of the previous pack size, or(ii) the increase in pro rata price if any taken by the company is in conformity with the provisions of paragraphs 20 (1) of DPCO
      3
      2013. The Company will be required to submit evidence (license issued by SDC/DCG(1), invoice and sample, duly certified by CA/CMA regarding the previous and the existing pack size of concerned formulation manufactured/marketed by it.

    • The Company has launched the new brand having the same composition as in earlier brand with a different brand name

      • (i) at the price equal to or less than that of the earlier brand, or

      • (ii) the increase in price taken by the company is in conformity with the provisions of paragraph 20 (1) of DPCO 2013.


      The Company will be required to submit evidence (license issued by SDC/DCG(I) and invoice and sample, duly certified by CA/CMA regarding the previous and the existing brand of concerned formulation manufactured/marketed by it

    • In cases where the brand has been procured/re-launched under a different name by another Company post-DPCO 2013, keeping the same composition of the formulation concerned as in the earlier brand (i) at the price equal to or less than that of the earlier brand, or (ii) the increase in price taken by the company is in conformity with the provisions of paragraph 20 (1) of DPCO 2013. The Company will be required to submit evidence (license issued by SDC/DCG(I) and invoice/sample, certified by CA/CMA) regarding the previous and the existing brand manufactured/marketed by it.


    The notice further states that any WPA case not coming under any of the above-said categories will be referred for price fixation and, after fixing the price concerned companies shall be liable to deposit overcharged amount along with interest from the date of overcharge, in addition to the penalty, as per provisions of paragraph 15 of the DPCO, 2013.


    The companies are instructed to submit the complete and requisite documents as stipulated. Companies are once again advised to check 'new drugs', if any, has been launched by them and obtain requisite price approval after complying with IPDMS requirements by submitting Form I prescribed in Schedule-II of DPCO, 2013, along with the documents as required by NPPA if not done earlier.


    Below is the attached notification for the same

    casesDepartment of PharmaceuticalsDPCODrugs Prices Control OrderexaminationGovernment of IndiaGuidelinesLaunchMinistry of Chemicals and FertilizersNational Pharmaceutical Pricing Authoritynew drugsNPPAPharma companiesprice approval

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok